Wedbush Reiterates Outperform on ARS Pharmaceuticals, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Andreas Argyrides reiterates an Outperform rating on ARS Pharmaceuticals (NASDAQ:SPRY) and maintains a $19 price target.

March 11, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Andreas Argyrides reaffirmed an Outperform rating on ARS Pharmaceuticals and kept the price target at $19.
The reaffirmation of an Outperform rating and a maintained price target of $19 by a reputable analyst suggests a positive outlook on the stock, likely leading to increased investor confidence and potential upward movement in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100